The PODIUM Study - a Three-arm Comparison of Target Therapies After Anti-TNFα in Ulcerative Colitis

Inclusion Criteria

• •Established diagnosis of UC according to the current European Crohn's and Colitis Organization (ECCO) guidelines7;
• •Age ≥ 18 years-old;
• •Capability of expressing informed consent;
• •Clinically active ulcerative colitis (cf. 'operative clinical measures', below) at baseline;
• •Initiation of vedolizumab, ustekinumab or JAK inhibitors (tofacitinib, upadacitinib or filgotinib) as second-line target therapy at baseline;
• •Previous treatment with at least one anti-TNFα drug licenced for the treatment of UC (i.e., infliximab, adalimumab and/or golimumab);
• •No exposure to vedolizumab, ustekinumab and JAK inhibitors before baseline;
• •At least 1 follow-up visit after baseline